Paper19822869
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.
Iwamoto FM and 7 others. Neurology, 2009. Cited by 264 papers, by iCite.
Cite this record
ConductScience Library. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Papers, record 19822869. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19822869
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Angiogenesis Inhibitors | Major topic |
| Antibodies, Monoclonal | Major topic |
| Brain Neoplasms | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Glioblastoma | Major topic |
| Adult | |
| Aged | |
| Antibodies, Monoclonal, Humanized | |
| Antineoplastic Combined Chemotherapy Protocols | |
| Bevacizumab | |
| Disease-Free Survival | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Neoplasm Recurrence, Local | |
| Prognosis | |
| Retrospective Studies | |
| Salvage Therapy | |
| Treatment Failure |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| 5 R01 CA076423-09 | NCI NIH HHS | United States | R01CA076423 | PubMed and NIH | NIH RePORTER |
| UO1 CA-105663-01 | NCI NIH HHS | United States | UO1CA105663 | PubMed | NIH RePORTER |
| 5 R01 CA121327-02 | NCI NIH HHS | United States | R01CA121327 | PubMed and NIH | NIH RePORTER |
| CA92629-06 | NCI NIH HHS | United States | PubMed | PubMed | |
| 2 P30 CA008748-27 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH | NIH RePORTER |
| 1N01 CM-62206 | NCI NIH HHS | United States | PubMed | PubMed | |
| P50CA092629 | NIH | NIH RePORTER | |||
| U01CA105663 | NIH | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 20385899 | Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. | https://conductscience.org/library/papers/20385899 |
Source PubMed
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17947719 | Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17947719 | PubMed |
| 2 | 19332770 | Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. | Neuro Oncol | 2009 | https://conductscience.org/library/papers/19332770 | PubMed |
| 3 | 16428489 | Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/16428489 | PubMed |
| 4 | 1512163 | Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. | Int J Radiat Oncol Biol Phys | 1992 | https://conductscience.org/library/papers/1512163 | PubMed |
| 5 | 18389177 | Time course of imaging changes of GBM during extended bevacizumab treatment. | J Neurooncol | 2008 | https://conductscience.org/library/papers/18389177 | PubMed |
| 6 | 18650835 | Modes of resistance to anti-angiogenic therapy. | Nat Rev Cancer | 2008 | https://conductscience.org/library/papers/18650835 | PubMed |
| 7 | 19249680 | Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. | Cancer Cell | 2009 | https://conductscience.org/library/papers/19249680 | PubMed |
| 8 | 19114704 | Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19114704 | PubMed |
| 9 | 19349600 | Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. | Neurology | 2009 | https://conductscience.org/library/papers/19349600 | PubMed |
| 10 | 12778165 | The biology of VEGF and its receptors. | Nat Med | 2003 | https://conductscience.org/library/papers/12778165 | PubMed |
| 11 | 16636248 | MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. | Neurology | 2006 | https://conductscience.org/library/papers/16636248 | PubMed |
| 12 | 18711427 | Response criteria for glioma. | Nat Clin Pract Oncol | 2008 | https://conductscience.org/library/papers/18711427 | PubMed |
| 13 | 17317837 | Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17317837 | PubMed |
| 14 | 18697955 | High-grade glioma before and after treatment with radiation and Avastin: initial observations. | Neuro Oncol | 2008 | https://conductscience.org/library/papers/18697955 | PubMed |
| 15 | 10561324 | Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. | J Clin Oncol | 1999 | https://conductscience.org/library/papers/10561324 | PubMed |
| 16 | 18328425 | HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. | Cancer Cell | 2008 | https://conductscience.org/library/papers/18328425 | PubMed |
| 17 | 11005565 | Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. | Neoplasia | 2000 | https://conductscience.org/library/papers/11005565 | PubMed |
| 18 | 17222792 | AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. | Cancer Cell | 2007 | https://conductscience.org/library/papers/17222792 | PubMed |
| 19 | 2358840 | Response criteria for phase II studies of supratentorial malignant glioma. | J Clin Oncol | 1990 | https://conductscience.org/library/papers/2358840 | PubMed |
| 20 | 12684411 | Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. | Clin Cancer Res | 2003 | https://conductscience.org/library/papers/12684411 | PubMed |
Cited by182
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 264 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42530690 | Spatial patterns of progression in reported glioblastoma cohorts after upfront chemoradiation and salvage therapy: a systematic review and meta-analysis. | J Neurooncol | 2026 | https://conductscience.org/library/papers/42530690 | PubMed |
| 42325608 | Phase 2 study of regorafenib in patients with progressive glioblastoma after failure of bevacizumab. | Neurooncol Adv | 2026 | https://conductscience.org/library/papers/42325608 | PubMed |
| 42028236 | Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial. | Neurooncol Adv | 2026 | https://conductscience.org/library/papers/42028236 | PubMed |
| 41211508 | Ambient ionization mass spectrometry in brain cancer diagnosis. | J Mass Spectrom Adv Clin Lab | 2025 | https://conductscience.org/library/papers/41211508 | PubMed |
| 40802280 | Liposomal honokiol enhance the anti-tumor effect of bevacizumab in glioblastoma by inhibiting autophagy. | Future Sci OA | 2025 | https://conductscience.org/library/papers/40802280 | PubMed |
| 40775789 | Glioblastoma metabolomics: uncovering biomarkers for diagnosis, prognosis and targeted therapy. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40775789 | PubMed |
| 40191237 | Translational Insights into Cancer-Associated Fibroblast Infiltration-Related Biomarkers in Glioblastoma and Their Clinical Prognostic Value. | Int J Gen Med | 2025 | https://conductscience.org/library/papers/40191237 | PubMed |
| 39925637 | A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma. | Neurooncol Adv | 2025 | https://conductscience.org/library/papers/39925637 | PubMed |
| 39775160 | Repeated 5-aminolevulinic acid mediated sonodynamic therapy using magnetic resonance guided focused ultrasound in rat brain tumour models. | Sci Rep | 2025 | https://conductscience.org/library/papers/39775160 | PubMed |
| 39001500 | The Use of Apparent Diffusion Coefficient Values for Differentiating Bevacizumab-Related Cytotoxicity from Tumor Recurrence and Radiation Necrosis in Glioblastoma. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39001500 | PubMed |
| 38596714 | Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design. | Neurooncol Adv | 2024 | https://conductscience.org/library/papers/38596714 | PubMed |
| 38473812 | Intrinsic and Microenvironmental Drivers of Glioblastoma Invasion. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38473812 | PubMed |
| 37684373 | Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial. | Commun Med (Lond) | 2023 | https://conductscience.org/library/papers/37684373 | PubMed |
| 37568606 | Advanced Magnetic Resonance Imaging in the Evaluation of Treated Glioblastoma: A Pictorial Essay. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37568606 | PubMed |
| 36987739 | Therapeutic potential of tumor treating fields for malignant brain tumors. | Cancer Rep (Hoboken) | 2023 | https://conductscience.org/library/papers/36987739 | PubMed |
| 36260832 | NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36260832 | PubMed |
| 36059707 | Metabolic management of microenvironment acidity in glioblastoma. | Front Oncol | 2022 | https://conductscience.org/library/papers/36059707 | PubMed |
| 35583721 | Initial results of a phase II trial of 18F-DOPA PET-guided re-irradiation for recurrent high-grade glioma. | J Neurooncol | 2022 | https://conductscience.org/library/papers/35583721 | PubMed |
| 35419519 | The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab. | Neurooncol Adv | 2022 | https://conductscience.org/library/papers/35419519 | PubMed |
| 35281485 | Advanced Imaging Techniques for Newly Diagnosed and Recurrent Gliomas. | Front Neurosci | 2022 | https://conductscience.org/library/papers/35281485 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19822869
GET https://conductscience.org/api/papers/v1/19822869/references?page=2